Company / Operating Income
Haemonetics Operating Income History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
$221.8M
FY2024
5-year range
$80.8M / $221.8M
FY2020-FY2024
Trend
+34.5%
vs FY2023
Sector context
#56 of 151
Health Care
What the data says
At $222M, Haemonetics's operating income ranks #56 of 151 in the Health Care sector. Operating Income has increased for 3 consecutive years, from $81M in FY2021 to $222M in FY2024.
Based on SEC 10-K filings.
$222M in FY2024 with a 5-year CAGR of +16.5%.
Improved from $156M to $222M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- +40.1%
- 5-Year CAGR
- +16.5%
- 10-Year CAGR
- -
Sector benchmark
#56 of 151 in Health CareTop 37% of 151This company $221.8M Sector average $716.7M
▼
-69.0% below sector average
Key checks
Key Insights
- Haemonetics's operating income has grown for 3 consecutive years.
- 5-year CAGR of +16.5%, indicating consistent growth.
- In FY2024, operating income increased 34.5% year-over-year.
- Ranks #56 out of 151 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score 0.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $221.8M | +34.5% |
| FY2023 | $164.9M | +5.7% |
| FY2022 | $156.0M | +93.2% |
| FY2021 | $80.8M | -10.0% |
| FY2020 | $89.7M | -13.2% |
| FY2019 | $103.4M | +23.7% |
| FY2018 | $83.5M | +48.8% |
| FY2017 | $56.2M | +389.8% |
| FY2016 | -$19.4M | +55.9% |
As of FY2024 · SEC 10-K · Updated Mar 28, 2026